Cargando…
Efficacy and Safety of Secukinumab in Chronic Plaque Psoriasis and Psoriatic Arthritis Therapy
Psoriasis is a chronic inflammatory skin disease affecting about 1–3% of the general population. Moderate-to-severe psoriasis is commonly associated with various comorbidities, including psoriatic arthritis (PsA) and cardio-metabolic disorders such as obesity, hypertension, diabetes, and metabolic s...
Autores principales: | Gisondi, Paolo, Dalle Vedove, Camilla, Girolomoni, Giampiero |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4065277/ https://www.ncbi.nlm.nih.gov/pubmed/24452484 http://dx.doi.org/10.1007/s13555-014-0042-5 |
Ejemplares similares
-
Apremilast in the therapy of moderate-to-severe chronic plaque psoriasis
por: Gisondi, Paolo, et al.
Publicado: (2016) -
Topographic Differential Diagnosis of Chronic Plaque Psoriasis: Challenges and Tricks
por: Gisondi, Paolo, et al.
Publicado: (2020) -
Central Pain Sensitization in Patients with Chronic Plaque Psoriasis
por: Bellinato, Francesco, et al.
Publicado: (2023) -
Reducing the Risk of Developing Psoriatic Arthritis in Patients with Psoriasis
por: Gisondi, Paolo, et al.
Publicado: (2022) -
Cost per Responder Analysis of Secukinumab versus Adalimumab in the Treatment of Psoriatic Disease
por: Gisondi, Paolo, et al.
Publicado: (2022)